Linked Life Data

8195833

Source:http://linkedlifedata.com/resource/pubmed/id/8195833

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1994-6-30
pubmed:abstractText
New diaminodiphenylsulfone inhibitors of dihydropteroate synthase are described with increased inhibitory activity against mycobacteria and plasmodia, whereas their side effect of methemoglobin formation could be suppressed. The optimization of diaminobenzylpyrimidines, inhibitors of dihydrofolate reductase, led to derivatives with increased inhibitory effect against mycobacteria, especially M. leprae and plasmodia. Some of these derivatives show autosynergism. Finally the combination of brodimoprim (BDP) and dapsone (DDS) was developed for the treatment of leprosy. First clinical trials in Paraguay and Ethiopia show that combinations of BDP/DDS and BDP/DDS plus rifampicin were highly effective and may become an alternative multi-drug therapy for the treatment of leprosy. The tolerance of the regimens used was generally good.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1120-009X
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
422-9
pubmed:dateRevised
2009-8-4
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria.
pubmed:affiliation
Institute for Experimental Biology and Medicine, Borstel, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Review, Research Support, Non-U.S. Gov't